Real-World Evidence: Five Facts You Need to Know

Publications
Published on:
March 31, 2022
Written by:
Romain Finas

Leveraging Real-World Data (RWD) is increasingly key for market access strategies and clinical research. Over the last 20 years, data gathered from electronic medical records, claims, medical devices, and the healthcare system has complemented clinical trial evidence—providing a clearer picture of the practice, outcomes, and costs of daily care. Now, RWD offers new possibilities to constitute synthetic control arms for clinical trials.   

We asked Romain Finas, Vice President of Real-World Evidence (RWE) at Alira Health, to share five important facts about RWD and tell us about the future challenges of RWD for Europe.

1. Investing in multimodal data infrastructure is a must, especially in oncology

Right now, mixing genomics data, imaging, and electronic medical records is the gold standard for anyone stratifying populations by treatment response or developing personalized medicine algorithms in oncology. Meeting these current—and future—research demands requires sizable investments as the incorporation of “omics” data—tumor, circulating DNA, or Whole Genome Sequencing—supposes a significant upfront and long-term financial investment. It is not only a question of data collection and monitoring but also the capability to (re)run sequencing based on biobanks according to the latest techniques. 

2. Non-fit-for-purpose data without a common data model applied in multiple centers

Beyond technical or data platform standards, it is essential to set common data models for each therapeutic area in collaboration with scientific associations, healthcare industries, and patient groups. This approach is key to focusing the collection efforts according to the targeted end-use of the data and providing relevant and qualitative sources. It also offers a real capability to develop multi-centric models reinforcing the value of the data for academic, institutions, or life science industries.  

3. AI will facilitate massive data collection, curation, and deidentification

Thanks to AI development—particularly natural language processing—data processing can move beyond craftsmanship. A significant part of the investment to run a cohort must be allocated to train AI to “read” and “check” data plausibility and deidentify sources. This will support the Clinical Research Associate role in data monitoring and improve the capability to control larger datasets in terms of co-variates, volume of patients, or nature of files (bioinformatics, imaging, structured or unstructured data).  

4. Public-private partnerships are key

Isolated sponsors (whether public or private) cannot succeed. The effort to design, collect, structure, enrich, or curate data demands long-term financing from full or permanent organizations. Public-private partnerships are now a true option to sustainably cover running costs. These partnerships also secure the generation of fit-for-purpose datasets that sponsors will pay for and help data sources stay ahead in the competitive global landscape of RWD-led research. 

5. Strong patient engagement is essential

Clearly communicating the benefits of data usage to patients, as well as the massive investment it takes to transform raw data into regulatory and scientific-grade sources, is critical. Proper patient engagement and onboarding also avoids controversy around the monetization of personal data when it’s for the common good. 

Alira Health is dedicated to the development of disease-centric data models and platforms co-designed by scientific associations, industry stakeholders, and patients. This represents a real opportunity to sustain Europe’s competitive advantages in the fierce global competition for health data 

At Alira Health, we are convinced that basing product access decisions on ethically collected, reliable data is a matter of sovereignty for healthcare institutions, especially in health technology assessment. It will also attract additional data research, offering patients earlier access to innovative health and care solutions. 

Related news

Multimedia May 10, 2022
VacciTalks: Behind the Scenes: Challenging Race of Vaccine Development
Join the 2nd episode of VacciTalks where together with vaccine expert Roberto Camerini we will peek behind the scenes of vaccine development and get an insider look at the difficulties,(...)
Market Access
Events May 9, 2022
7e Journée start-up innovantes du dispositif médical
Clinical Digital Health Market Access MedTech Research & Development
Multimedia April 28, 2022
Alira Health’s Transformation Talks: Real-World Data to Support HTAs in Europe
Learn more about RWD as a support in HTAs and its direct impact on HTAs budgets, results, and even patient outcomes by listening to this episode of Transformation Talks.
Clinical Market Access RWE
Publications April 20, 2022
White Paper: Next Generation Therapies: Access, Pricing and Ethical Issues in Perspective
In this white paper, we will explore wide range of new therapies we term “Next Generation Therapies” and challenges related to them.
Market Access
Multimedia April 15, 2022
Alira Health’s Transformation Talks: Real-World Evidence Strategy Playbook
As a special guest, our episode “Real-World Evidence Strategy Playbook” with Romain Finas, Vice President of Real-World Evidence at Alira Health, is now live! Listen to this podcast(...)
Clinical RWE
Publications March 31, 2022
Real-World Evidence: Five Facts You Need to Know
Learn more about RWD and its future challenges for Europe, we asked Romain Finas, Vice President of Real-World Evidence (RWE) at Alira Health, to share five facts that you need to know about it.
Market Access RWE
Publications March 25, 2022
Early Access Programs: Keys to Success
Discover Alira Health’s top five recommendations to building a successful Early Access Programs (EAP). 
Market Access
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.